Notice of Closed Meeting, 9523-9524 [2019-04848]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 51 / Friday, March 15, 2019 / Notices
patentable material, and personal
information concerning individuals
associated with the grant applications,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease, Disability,
and Injury Prevention and Control Special
Emphasis Panel (SEP)—GH19–013,
Advancing Infectious Disease Detection and
Response in Liberia.
Date: April 30, 2019.
Time: 9:00 a.m.–2:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Hylan
Shoob, Ph.D., Scientific Review Officer,
Center for Global Health, CDC, 1600 Clifton
Drive, Atlanta, GA 30329–4027, (404) 639–
4796; HShoob@cdc.gov.
The Chief Operating Officer, Centers for
Disease Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for both
the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Sherri Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2019–04825 Filed 3–14–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Council for the Elimination of
Tuberculosis (ACET)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
CDC announces the following meeting
of the Advisory Council for the
Elimination of Tuberculosis Meeting
(ACET). This meeting is open to the
public, limited only by the space
available. The meeting room will
accommodate up to 60 people. The
public is also welcome to listen to the
meeting by telephone, limited only by
the number of ports available (100).
Time will be available for public
comment. The public is welcome to
submit written comments in advance of
the meeting. Comments should be
submitted in writing by email to the
contact person listed below. The
deadline for receipt is Monday, April
15, 2019. Persons who desire to make an
amozie on DSK9F9SC42PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:53 Mar 14, 2019
Jkt 247001
oral statement, may request it at the
time of the public comment period on
April 16, 2019 at 3:20 p.m. EDT.
The meeting will be held on
April 16, 2019, 10:00 a.m. to 3:30 p.m.,
EDT.
DATES:
8 Corporate Blvd., Building
8, Conference Rooms 1A and 1B,
Atlanta, Georgia 30329 and Web
conference: 1–877–927–1433 and
participant passcode: 12016435 and
https://adobeconnect.cdc.gov/r5p8l
2tytpq/.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Margie Scott-Cseh, Committee
Management Specialist, CDC, 1600
Clifton Road NE, Mailstop: E–07,
Atlanta, Georgia 30329–4018, telephone
(404) 639–8317; zkr7@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: This Council advises and
makes recommendations to the
Secretary of Health and Human
Services, the Assistant Secretary for
Health, and the Director, CDC, regarding
the elimination of tuberculosis.
Specifically, the Council makes
recommendations regarding policies,
strategies, objectives, and priorities;
addresses the development and
application of new technologies; and
reviews the extent to which progress has
been made toward eliminating
tuberculosis.
Matters to be considered: The agenda
will include discussions on (1)
Overview of the ‘‘Digital Bridge’’; (2)
Overview of tuberculosis care for
migrant detainees; (3) Overview of
infrastructure and mechanisms to
develop, update, and maintain HIV
guidelines; and (4) Update from ACET
workgroups. Agenda items are subject to
change as priorities dictate.
The Chief Operating Officer, Centers
for Disease Control and Prevention, has
been delegated the authority to sign
Federal Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Sherri Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2019–04822 Filed 3–14–19; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
9523
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP)
CK19–002, Quantifying Contact Rates
and Mixing Patterns in Workers in NonHealthcare Work Settings in the United
States and CK19–004, Study to Assess
the Risk of Blood Borne Transmission of
Classic Forms of Creutzfeldt-Jakob
Disease (CJD).
Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the Disease, Disability,
and Injury Prevention and Control
Special Emphasis Panel (SEP); CK19–
002, Quantifying Contact Rates and
Mixing Patterns in Workers in NonHealthcare Work Settings in the United
States and CK19–004, Study to Assess
the Risk of Blood Borne Transmission of
Classic Forms of Creutzfeldt-Jakob
Disease (CJD); May 7, 2019; 10:00 a.m.–
5:00 p.m., (EDT) which was published
in the Federal Register on December 26,
2018, Volume 83, Number 246, pages
66270.
The meeting is being amended to add
CK17–005SUPP, Vector-Borne Disease
Regional Centers of Excellence. The
meeting is closed to the public.
Contact: Gregory Anderson, M.S.,
M.P.H., Scientific Review Officer, CDC,
1600 Clifton Road NE, Mailstop E60,
Atlanta, Georgia 30333, (404) 718–8833,
gca5@cdc.gov.
The Chief Operating Officer, Centers
for Disease Control and Prevention, has
been delegated the authority to sign
Federal Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Sherri Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2019–04823 Filed 3–14–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
Frm 00048
Fmt 4703
Sfmt 4703
E:\FR\FM\15MRN1.SGM
15MRN1
9524
Federal Register / Vol. 84, No. 51 / Friday, March 15, 2019 / Notices
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Chief Operating Officer, CDC,
pursuant to Public Law 92–463. The
grant applications and the discussions
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the grant applications,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
GH19–003, Advancing Infectious
Disease Detection and Response in
Senegal; GH19–006, Advancing
Infectious Disease Detection and
Response in Indonesia; GH19–008,
Advancing Infectious Disease Detection
and Response in Uganda; GH19–009,
Advancing Infectious Disease Detection
and Response in Vietnam; GH19–010,
Advancing Disease Detection and
Response in Nigeria; and GH19–015,
Strengthening National Capacity for
Malaria Operations Research in Malawi.
Date: April 24, 2019.
Time: 9:00 a.m.–2:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
FOR FURTHER INFORMATION CONTACT:
amozie on DSK9F9SC42PROD with NOTICES
Hylan Shoob, Ph.D., Scientific Review
Officer, Center for Global Health, CDC,
1600 Clifton Drive, Atlanta, GA 30329–
4027,(404) 639–4796; HShoob@cdc.gov.
The Chief Operating Officer, Centers
for Disease Control and Prevention, has
been delegated the authority to sign
Federal Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Sherri Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2019–04848 Filed 3–14–19; 8:45 am]
BILLING CODE 4163–18–P
VerDate Sep<11>2014
16:53 Mar 14, 2019
Jkt 247001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket Number CDC–2019–0015, NIOSH–
153–E]
Request for the Technical Review of 10
Draft Skin Notation Assignments and
Skin Notation Profiles
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Request for information and
comment.
AGENCY:
The National Institute for
Occupational Safety and Health of the
Centers for Disease Control and
Prevention announces the availability of
10 draft skin notation profile documents
now available for public comment
entitled:
Skin notation profile: Cyclohexanol
Skin notation profile: Cyclohexanone
Skin notation profile: Cyclonite
Skin notation profile: Diacetyl and 2,3Pentanedione
Skin notation profile:
Diethylenetriamine
Skin notation profile: beta-Chloroprene
Skin notation profile: Chlorodiphenyl
42% Chlorine
Skin notation profile: Chlorodiphenyl
54% Chlorine
Skin notation profile: Dioxane
Skin notation profile: 2,4-Toluene
diisocyanate, 2,6-Toluene
diisocyanate, and the mixture of 2,4and 2,6-Toluene diisocyanate
To view the notice and related
materials, visit https://
www.regulations.gov and enter CDC–
2019–0015 in the search field and click
‘‘Search.’’
DATES: Electronic or written comments
must be received by May 14, 2019.
ADDRESSES: You may submit comments,
identified by CDC–2019–0015 and
docket number NIOSH–153–E, by any of
the following methods:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: National Institute for
Occupational Safety and Health, NIOSH
Docket Office, 1090 Tusculum Avenue,
MS C–34, Cincinnati, Ohio 45226–1998.
Instructions: All information received
in response to this notice must include
the agency name and docket number
[CDC–2019–0015; NIOSH–153–E]. All
relevant comments received will be
SUMMARY:
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
posted without change to https://
www.regulations.gov, including any
personal information provided. All
electronic comments should be
formatted as Microsoft Word. For access
to the docket to read background
documents or comments received, go to
https://www.regulations.gov. All
information received in response to this
notice will also be available for public
examination and copying at the NIOSH
Docket Office, 1150 Tusculum Avenue,
Room 155, Cincinnati, OH 45226–1998.
FOR FURTHER INFORMATION CONTACT:
Naomi Hudson, NIOSH/EID, Robert A.
Taft Laboratories, 1090 Tusculum
Avenue, MS–C32, Cincinnati, OH
45226. Telephone: (513) 533–8388 (not
a toll free number).
SUPPLEMENTARY INFORMATION: The
National Institute for Occupational
Safety and Health (NIOSH) of the
Centers for Disease Control and
Prevention (CDC) is conducting a public
review of the draft skin notations and
support technical documents, entitled
Skin Notations Profiles, for 10
chemicals. NIOSH is requesting
technical reviews of the draft Skin
Notation Profiles.
Background: In 2009, NIOSH
published Current Intelligence Bulletin
(CIB) 61—A Strategy for Assigning New
NIOSH Skin Notations [NIOSH 2009–
147; https://www.cdc.gov/niosh/docs/
2009-147/pdfs/2009-147.pdf]. The CIB
presents a strategic framework that is a
form of hazard identification designed
to do the following:
1. Ensure that the assigned skin
notations reflect the contemporary state
of scientific knowledge.
2. Provide transparency behind the
assignment process.
3. Communicate the hazards of
chemical exposures of the skin.
4. Meet the needs of health
professionals, employers, and other
interested parties in protecting workers
from chemical contact with the skin.
This strategy involves the assignment of
multiple skin notations for
distinguishing systemic (SYS), direct
(DIR), and sensitizing (SEN) effects
caused by exposure of skin (SK) to
chemicals.
Information Needs: To facilitate the
review of these documents, NIOSH
requests that the following questions be
taken into consideration:
1. Does this document clearly outline
the systemic health hazards associated
with exposures of the skin to the
chemical? If not, what specific
information is missing from the
document?
2. If the SYS or SYS (FATAL)
notations are assigned, are the rationale
E:\FR\FM\15MRN1.SGM
15MRN1
]]>Agencies
[Federal Register Volume 84, Number 51 (Friday, March 15, 2019)]
[Notices]
[Pages 9523-9524]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-04848]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
[[Page 9524]]
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Chief Operating
Officer, CDC, pursuant to Public Law 92-463. The grant applications and
the discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)--GH19-003, Advancing Infectious
Disease Detection and Response in Senegal; GH19-006, Advancing
Infectious Disease Detection and Response in Indonesia; GH19-008,
Advancing Infectious Disease Detection and Response in Uganda; GH19-
009, Advancing Infectious Disease Detection and Response in Vietnam;
GH19-010, Advancing Disease Detection and Response in Nigeria; and
GH19-015, Strengthening National Capacity for Malaria Operations
Research in Malawi.
Date: April 24, 2019.
Time: 9:00 a.m.-2:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant applications.
FOR FURTHER INFORMATION CONTACT: Hylan Shoob, Ph.D., Scientific Review
Officer, Center for Global Health, CDC, 1600 Clifton Drive, Atlanta, GA
30329-4027,(404) 639-4796; HShoob@cdc.gov.
The Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Sherri Berger,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2019-04848 Filed 3-14-19; 8:45 am]
BILLING CODE 4163-18-P
